Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ImmunoCellular Therapeutics, Ltd. | rrd372313.htm |
| EX-99 - PRESS RELEASE DATED MARCH 5, 2013 - ImmunoCellular Therapeutics, Ltd. | rrd372313_39349.htm |
| Condensed Balance Sheets | ||||||||
| 12/31/2012 | 12/31/2011 | |||||||
|
|
|
|
|
|||||
| Cash | $ | 26,216,668 | $ | 6,653,168 | ||||
| Other current assets | 714,508 | 91,286 | ||||||
| Non current assets | 88,025 | 406,303 | ||||||
|
|
|
|
|
|||||
| $ | 27,019,201 | $ | 7,150,757 | |||||
|
|
|
|
|
|||||
| Current liabilities | $ | 1,098,307 | $ | 1,761,289 | ||||
| Warrant liabilities | 2,852,880 | 2,157,408 | ||||||
| Shareholders' equity | 23,068,014 | 3,232,060 | ||||||
|
|
|
|
|
|||||
| $ | 27,019,201 | $ | 7,150,757 | |||||
|
|
|
|
|
|||||
| Condensed Statement of Operations | ||||||||
| Year | Year | |||||||
| ended | ended | |||||||
| 12/31/2012 | 12/31/2011 | |||||||
|
|
|
|
|
|||||
| Revenue | $ | - | $ | - | ||||
| Research and development | 7,711,233 | 4,988,612 | ||||||
| Stock based compensation | 496,007 | 1,190,133 | ||||||
| General and administrative | 3,619,291 | 2,446,757 | ||||||
|
|
|
|
|
|||||
| Loss before other expenses | (11,826,531) | (8,625,502) | ||||||
| Interest income | 8,609 | 4,346 | ||||||
| Financing expense | (397,294) | - | ||||||
| Change in fair value of warrant liabilities | (2,279,923) | 2,901,253 | ||||||
|
|
|
|
|
|||||
| Net loss | (14,495,139) | (5,719,903) | ||||||
| Deemed dividend on preferred stock | 0 | 0 | ||||||
|
|
|
|
|
|||||
| Net loss available to common stockholders | $ | (14,495,139) | $ | (5,719,903) | ||||
|
|
|
|
|
|||||